» Articles » PMID: 28018857

Murine Models of Splenic Marginal Zone Lymphoma: A Role for ?

Overview
Journal Front Oncol
Specialty Oncology
Date 2016 Dec 27
PMID 28018857
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Dozens of murine models of indolent and aggressive B-cell lymphomas have been generated to date. These include those manifesting chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), as well as xenografts of mantle cell lymphoma (MCL). These models have led to an improved understanding of disease etiology, B-cell biology, immunomodulation, and the importance of the tumor microenvironment. Despite these efforts in CLL, DLBCL, and MCL, considerably little progress toward a model of splenic marginal zone lymphoma (SMZL) has been accomplished. Herein, we describe the similarities and differences between CLL, MCL, and SMZL and highlight effective murine models that mimic disease in the two former, in hopes of informing a potential model of the latter. At the time of writing this review, the precise molecular events of SMZL remain to be determined and a treatment regimen remains to be identified. Therefore, based on the efforts put forth in the B-cell lymphoma field throughout the past three decades, the established role of in B- and T-cell biology as an oncogene or tumor suppressor, and the recurrent deletion or loss of heterozygosity (LOH) of 7q in many cancers, we make recommendations for a murine model of SMZL.

Citing Articles

Distinct oncogenic phenotypes in hematopoietic specific deletions of Trp53.

Palanichamy J, Tran T, King J, Katzman S, Ritter A, Sharma G Sci Rep. 2023; 13(1):7490.

PMID: 37160922 PMC: 10169790. DOI: 10.1038/s41598-023-33949-8.


New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas.

Donzel M, Baseggio L, Fontaine J, Pesce F, Ghesquieres H, Bachy E Curr Oncol. 2021; 28(5):3430-3447.

PMID: 34590593 PMC: 8482189. DOI: 10.3390/curroncol28050297.


Deciphering splenic marginal zone lymphoma pathogenesis: the proposed role of microRNA.

Robinson J, Cutucache C Oncotarget. 2018; 9(52):30005-30022.

PMID: 30042829 PMC: 6057449. DOI: 10.18632/oncotarget.25487.

References
1.
Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G . KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2014; 29(5):1177-85. DOI: 10.1038/leu.2014.330. View

2.
Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D . The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 1994; 83(6):1558-62. View

3.
Arribas A, Rinaldi A, Mensah A, Kwee I, Cascione L, Robles E . DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood. 2015; 125(12):1922-31. PMC: 4416938. DOI: 10.1182/blood-2014-08-596247. View

4.
Hough M, Reis M, Singaraja R, Bryce D, Kamel-Reid S, Dardick I . A model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice. Proc Natl Acad Sci U S A. 1998; 95(23):13853-8. PMC: 24927. DOI: 10.1073/pnas.95.23.13853. View

5.
Ward J, Perkins S, Chattopadhyay S, Hursting S, Morse 3rd H . Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice. Lab Invest. 1999; 79(1):3-14. View